Vinge advises Bridgepoint Development Capital III and Bridgepoint Europe VI (”Bridgepoint”), founders as well as the other shareholders in connection with Cinven, an international private equity firm, acquiring a significant stake in Vitamin Well Group (“Vitamin Well”) and thereby becoming the new lead investor, while Bridgepoint, founders and the other shareholders will retain significant minority stakes following the transaction.

Vitamin Well, founded in 2008 and headquartered in Stockholm, is a fast-growing functional foods and beverage group offering premium products for health-conscious and active consumers. Today, the group has approximately 500 employees and a broad multi-brand product portfolio, including the core brands Vitamin Well (vitamin and mineral-enriched beverages), NOCCO (energy drinks) and Barebells (protein bars and shakes), which are sold internationally in more than 40 markets.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Daniel Rosvall, Samra Tesser, Carl Fredrik Wachtmeister, Robin Fagerström, Sara Passandideh and Lovisa Jonassen (M&A), Albert Wållgren, Karl-Gustaw Tobola and Josef Groow (Banking and Finance), Ebba Svenburg and Jonna Skog (Employment), Arvid Axelryd (Intellectual Property), Karolina Cohrs (Real Estate), Christoffer Nordin, Martin Boström, Carla Zachariasson and Arthur Kinski (Commercial Agreements, IT and GDPR) David Olander, Lovisa Lewin and Hampus Peterson (EU and FDI Regulatory) Anders Leissner, Tyra von Mentzer and Gulestan Ali (Compliance), Jessica Öijer, Cecilia Loctander and Christoffer Widström (Transaction Support Coordinators).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025